Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
25 Results for "
antinociceptive potentials
" in MedChemExpress (MCE) Product Catalog:
Products (25)
25 Results for "antinociceptive potentials" in MCE Product Catalog:
3
3
Research Areas:
Guanine hydrochloride is one of the fundamental components of nucleic acids (DNA and RNA). Guanine hydrochloride is a purine derivative, consisting of a fused pyrimidine-imidazole ring system with conjugated double bonds. Guanine hydrochloride has the potential to serve as a large-capacity N pool. Guanine hydrochloride has cytotoxic, antinociceptive and neuroprotective effects .
1
Category:
Flavonols other families Flavonoids Monophenols Phenols Plants Disease Research Fields Inflammation/Immunology
Target:
Synonyms: NIH 10815
Target:
Research Areas:
SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
Cat. No.: HY-Y1055S
CAS No.: 201489-20-5
Cat. No.: HY-Y1055S3
CAS No.: 168566-53-8
Target:
Research Areas:
Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with Ki values of >1000, 68.5, >1000, >1000 nM for A1AR, A2AAR, A2BAR, A3AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases .
Target:
Research Areas:
CB1/2 agonist 1 is a potent and cross the blood-brain barrier CB1/2 agonist with EC50s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis .
Cat. No.: HY-Y1055S1
CAS No.: 202407-12-3
Cat. No.: HY-W777809
CAS No.: 1246814-70-9
Cat. No.: HY-122953
CAS No.: 41498-80-0
Target:
Cat. No.: HY-136654
CAS No.: 492451-07-7
Target:
Research Areas:
LPK-26 hydrochloride is a selective kappa-opioid receptor agonist with a Ki of 0.68 nM. LPK-26 exhibits potent antinociceptive effects with low physical dependence potential and can be utilized in relevant research .
Cat. No.: HY-126232
CAS No.: 50932-20-2
Category:
Infection Plantaginaceae Veronica officinalis L. Iridoids Terpenoids Plants Disease Research Fields
Target:
Cat. No.: HY-Y1055S4
Cat. No.: HY-101202A
CAS No.: 1217643-87-2
Synonyms: (Rac)-NIH 10815
Target:
Research Areas:
(Rac)-SNC80 is a racemate of SNC80 (HY-101202). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
Cat. No.: HY-W778114
CAS No.: 1207525-05-0
Cat. No.: HY-Y1055S2
Cat. No.: HY-B0380B
CAS No.: 1456509-46-8
Synonyms: GIC-1001
Target:
Research Areas:
Trimebutine 3-TCBS (GIC-1001) is an innovative formulation designed to release hydrogen sulfide (H2S) in vivo. This compound combines trimebutine with an H2S-releasing antagonist (phenyl 3-thiocarbamate) and exhibits enhanced anti-nociceptive effects in a mouse colonic distension model, superior to conventional trimebutine. GIC-1001 can reduce visceral pain and discomfort associated with lumen distension in a dose-dependent manner, showing potential superiority .
Cat. No.: HY-159923
CAS No.: 2131199-52-3
Target:
Research Areas:
BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
